These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20406744)

  • 21. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reporting and representation of race/ethnicity in published randomized trials.
    Berger JS; Melloni C; Wang TY; Dolor RJ; Frazier CG; Samad Z; Peterson ED; Mark DB; Newby LK
    Am Heart J; 2009 Nov; 158(5):742-7. PubMed ID: 19853691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies with group treatments required special power calculations, allocation methods, and statistical analyses.
    Faes MC; Reelick MF; Perry M; Olde Rikkert MG; Borm GF
    J Clin Epidemiol; 2012 Feb; 65(2):138-46. PubMed ID: 21856120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some practical problems in implementing randomization.
    Downs M; Tucker K; Christ-Schmidt H; Wittes J
    Clin Trials; 2010 Jun; 7(3):235-45. PubMed ID: 20484491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inefficiency of randomization methods that balance on stratum margins and improvements with permuted blocks and a sequential method.
    Kaiser LD
    Stat Med; 2012 Jul; 31(16):1699-706. PubMed ID: 22437508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical issues in the use of dynamic allocation methods for balancing baseline covariates.
    Pond GR
    Br J Cancer; 2011 May; 104(11):1711-5. PubMed ID: 21540857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalized multidimensional dynamic allocation method.
    Lebowitsch J; Ge Y; Young B; Hu F
    Stat Med; 2012 Dec; 31(28):3537-44. PubMed ID: 22736449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are we really that blind?
    van der Meulen EA
    J Biopharm Stat; 2005; 15(3):479-89. PubMed ID: 15920892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design issues in head and neck clinical trials: a statistician's perspective.
    Fortpied C; Liberatoscioli C; Bogaerts J
    Anticancer Drugs; 2011 Aug; 22(7):682-7. PubMed ID: 21709617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brick tunnel randomization for unequal allocation to two or more treatment groups.
    Kuznetsova OM; Tymofyeyev Y
    Stat Med; 2011 Apr; 30(8):812-24. PubMed ID: 21432876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The "best balance" allocation led to optimal balance in cluster-controlled trials.
    de Hoop E; Teerenstra S; van Gaal BG; Moerbeek M; Borm GF
    J Clin Epidemiol; 2012 Feb; 65(2):132-7. PubMed ID: 21840173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.
    Nomura S; Miyauchi Y; Ajisawa Y; Isogaya K; Sozu T
    Ther Innov Regul Sci; 2020 Sep; 54(5):1185-1191. PubMed ID: 32865800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimisation for the design of parallel cluster-randomised trials: An evaluation of balance in cluster-level covariates and numbers of clusters allocated to each arm.
    Martin J; Middleton L; Hemming K
    Clin Trials; 2023 Apr; 20(2):111-120. PubMed ID: 36661245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting a randomization method for a multi-center clinical trial with stochastic recruitment considerations.
    Sverdlov O; Ryeznik Y; Anisimov V; Kuznetsova OM; Knight R; Carter K; Drescher S; Zhao W
    BMC Med Res Methodol; 2024 Feb; 24(1):52. PubMed ID: 38418968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data collection in cancer clinical trials: Too much of a good thing?
    O'Leary E; Seow H; Julian J; Levine M; Pond GR
    Clin Trials; 2013 Aug; 10(4):624-32. PubMed ID: 23785066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling clinical cancer research across the Atlantic: a review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade.
    Pentheroudakis G; Krikelis D; Cervantes A; Vermorken J; Pavlidis N
    Cancer Treat Rev; 2012 Oct; 38(6):560-5. PubMed ID: 22209684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample Size Calculation in Oncology Trials: Quality of Reporting and Implications for Clinical Cancer Research.
    Bariani GM; de Celis Ferrari AC; Precivale M; Arai R; Saad ED; Riechelmann RP
    Am J Clin Oncol; 2015 Dec; 38(6):570-4. PubMed ID: 24401665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer.
    Komiya T; Perez RP; Erickson KD; Huang CH
    Thorac Cancer; 2016 Jan; 7(1):66-71. PubMed ID: 26813229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.